Delving into the Latest Updates on GRT-6010 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

GRT 6010

Target

OOR

Action

agonists

Mechanism

OOR agonists(Nociceptin receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Neuralgia

Originator Organization

Grunenthal SA

Active Organization-

Inactive Organization

Grünenthal GmbHGrunenthal SA

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

A randomized, single-center, double-blind, placebo-controlled, 2-way cross-over, single oral administration trial to evaluate blood-borne biomarker candidates to predict NOP receptor activation using GRT6010 as NOP receptor agonist in healthy human subjects. - Evaluation biomarker to predict NOP receptor activation using GRT6010

Start Date07 May 2012

Sponsor / Collaborator

Grünenthal GmbH

NCT01485094

/ TerminatedPhase 2

Evaluation of the Efficacy, Tolerability, and Safety of 7 Days of Treatment With GRT6010 or Pregabalin in Comparison to Placebo in Subjects With Peripheral Neuropathic Pain.

The purpose of this trial is to determine whether a novel analgesic is effective in treating of neuropathic pain caused by herpetic infection, surgery, or trauma.

Start Date01 Feb 2012

Sponsor / Collaborator

Grünenthal GmbH

100 Clinical Results associated with GRT-6010

Login to view more data

100 Translational Medicine associated with GRT-6010

Login to view more data

100 Patents (Medical) associated with GRT-6010

Login to view more data

100 Deals associated with GRT-6010

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuralgia	Phase 2	Germany	Grünenthal GmbH	01 Feb 2012
Neuralgia	Phase 2	Germany	Grunenthal SA	01 Feb 2012
Neuralgia	Phase 2	Hungary	Grünenthal GmbH	01 Feb 2012
Neuralgia	Phase 2	Hungary	Grunenthal SA	01 Feb 2012
Neuralgia	Phase 2	Poland	Grunenthal SA	01 Feb 2012
Neuralgia	Phase 2	Poland	Grünenthal GmbH	01 Feb 2012
Neuralgia	Phase 2	United Kingdom	Grunenthal SA	01 Feb 2012
Neuralgia	Phase 2	United Kingdom	Grünenthal GmbH	01 Feb 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01485094 (CTgov)	Phase 2	Neuralgia	114	Matching Placebo (Matching Placebo)	tibtpbgbzf(pltblqyyuj) = bselxtfync dagomnqpyr (vibhwdkmah, 2.15) View more	-	02 Oct 2014
				GRT6010 (GRT6010)	tibtpbgbzf(pltblqyyuj) = aozyrkuzob dagomnqpyr (vibhwdkmah, 1.73) View more